Show simple item record

dc.contributor.authorLeiro Fernández, Virginia
dc.contributor.authorDe Chiara Prada, Loretta 
dc.contributor.authorRodríguez Girondo, Mar
dc.contributor.authorBotana Rial, María Isabel
dc.contributor.authorValverde Pérez, Diana 
dc.contributor.authorNúñez Delgado, Manuel
dc.contributor.authorFernández Villar, Alberto
dc.date.accessioned2021-05-03T12:29:51Z
dc.date.available2021-05-03T12:29:51Z
dc.date.issued2019-09-20
dc.identifier.citationCancers, 11(10): 1408 (2019)spa
dc.identifier.issn20726694
dc.identifier.urihttp://hdl.handle.net/11093/2076
dc.description.abstractThe evaluation of mediastinal lymph nodes is critical for the correct staging of patients with lung cancer (LC). Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) is a minimally invasive technique for mediastinal staging, though unfortunately lymph node micrometastasis is often missed by cytological analysis. The aim of this study was to evaluate the predictive capacity of methylation biomarkers and provide a classification rule for predicting malignancy in false negative EBUS-TBNA samples. The study included 112 patients with a new or suspected diagnosis of LC that were referred to EBUS-TBNA. Methylation of p16/INK4a, MGMT, SHOX2, E-cadherin, DLEC1, and RASSF1A was quantified by nested methylation-specific qPCR in 218 EBUS-TBNA lymph node samples. Cross-validated linear regression models were evaluated to predict malignancy. According to EBUS-TBNA and final diagnosis, 90 samples were true positives for malignancy, 110 were true negatives, and 18 were false negatives. MGMT, SHOX2, and E-cadherin were the methylation markers that better predicted malignancy. The model including sex, age, short axis diameter and standard uptake value of adenopathy, and SHOX2 showed 82.7% cross-validated sensitivity and 82.4% specificity for the detection of malignant lymphadenopathies among negative cytology samples. Our results suggest that the predictive model approach proposed can complement EBUS-TBNA for mediastinal staging.en
dc.description.sponsorshipInstituto de Salud Carlos III | Ref. PI09/90385spa
dc.description.sponsorshipInstituto de Salud Carlos III | Ref. RETIC-FIS-ISCIII RD09/0076/00011spa
dc.description.sponsorshipXunta de Galicia | Ref. 09CSA053905PFspa
dc.language.isoengen
dc.publisherCancersspa
dc.rightsAttribution 4.0 International (CC BY 4.0)
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.titleMethylation assessment for the prediction of malignancy in mediastinal adenopathies obtained by endobronchial ultrasound-guided transbronchial needle aspiration in patients with lung canceren
dc.typearticlespa
dc.rights.accessRightsopenAccessspa
dc.identifier.doi10.3390/cancers11101408
dc.identifier.editorhttps://www.mdpi.com/2072-6694/11/10/1408spa
dc.publisher.departamentoBioquímica, xenética e inmunoloxíaspa
dc.publisher.grupoinvestigacionXenómica e Biomedicinaspa
dc.subject.unesco32 Ciencias Médicasspa
dc.subject.unesco3201.01 Oncologíaspa
dc.subject.unesco2409 Genéticaspa
dc.subject.unesco2412 Inmunologíaspa
dc.date.updated2021-05-02T11:16:59Z
dc.computerCitationpub_title=Cancers|volume=11|journal_number=10|start_pag=1408|end_pag=spa
dc.referencesThis research was funded by AEER (Antonio Castella 2010), FIS-FEDER (PI09/90385) and Xunta de Galicia (09CSA053905PF). The samples used in this work belong to the Biobank from the CHUVI (RETIC-FIS-ISCIII RD09/0076/00011)spa


Files in this item

[PDF]

    Show simple item record

    Attribution 4.0 International (CC BY 4.0)
    Except where otherwise noted, this item's license is described as Attribution 4.0 International (CC BY 4.0)